BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, December 8, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 12, 2007

View Archived Issues

Low-dose, high-dose intensity decitabine beneficial in myelodysplastic syndrome

Read More

Erythrocyte Gs: a novel target for the treatment of malaria

Read More

Selegiline skin patch studied for smoking cessation

Read More

Pharmion reflects on 2006, milestones for 2007

Read More

Labopharm's once-daily tramadol rolled out across Europe

Read More

Novel inhibitors of Rho kinase profiled at GlaxoSmithKline

Read More

Genentech acquires oncology program from Amphora Discovery

Read More

Organon collaborates with Huya Bioscience

Read More

AVI and Eleos sign crosslicense agreement for p53 antisense drugs

Read More

Alnylam and Inex to use liposomal delivery technology for RNAi therapeutics

Read More

Ceftobiprole meets endpoints in pivotal complicated skin infections study

Read More

Cannabinoids reduce melanoma growth

Read More

Combinations with pazopanib produce synergistic cytotoxicity in multiple myeloma

Read More

Acid sphingomyelinase replacement therapy to be evaluated in Niemann-Pick disease

Read More

Recent Pfizer patents disclose novel analgesic agents

Read More

Recent Merck KGaA patent describes new therapeutic agents for skin hyperpigmentation

Read More

New antidiabetic agents disclosed in recent patent literature

Read More

Xytis cleared to begin phase II study of anatibant for traumatic brain injury

Read More

Phase III study evaluates Axid OS for use in infants with GERD

Read More

Napo to acquire intellectual property, plans financing

Read More

BG-12 begins phase III for relapsing-remitting MS

Read More

Phase II trials in China to study Rh-Apo2L in cancer

Read More

Phase III program under way for cetrorelix in BPH

Read More

AL-108 to be studied for cognitive impairment in schizophrenia

Read More

rEV-131 misses primary endpoint in phase II postcataract inflammation trial

Read More

Cell Therapeutics updates progress of Xyotax and pixantrone programs

Read More

Biopure receives opinion letter in U.K. on Hemopure MAA

Read More

Italian Ministry of Health requests Iplex be made available for ALS

Read More

Recentin announced as global trademark for AZD-2171

Read More

InteKrin licenses INT-131 from Amgen

Read More

Japanese filing for mirtazapine planned for mid-2007

Read More

Solvay and Wyeth expand neuroscience agreement into antipsychotic research

Read More

SPA offered for Ark's phase III study of Trinam

Read More

First launch for hepatitis B vaccine Supervax in Argentina

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 5, 2025.
  • Mesothelin is biomarker, potential target in arthritic bone damage

    BioWorld Science
    In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
  • 3D rendering of prion structure

    Epigenetic technology could eliminate misfolded prion proteins

    BioWorld Science
    The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
  • Novo Nordisk semaglutide pill

    CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

    BioWorld
    A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing